Filed in archive
Studies
, Treatment
by Gloria Gamat on May 9, 2007

These were the findings of a new study by researchers at Wake Forest University School of Medicine recently reported at the annual meeting of the American Geriatrics Society in Seattle.
The kind of ACE inhibitors that are centrally active: captropril (Capoten®), fosinopril (Monopril®), lisinopril (Prinivil® or Zestri®), perindopril (Aceon®), ramipril (Altace®) and trandolapril (Mavik®).
Intake of these centrally active ACE (angiotensin-converting enzyme) inhibitors have been found to lower rates of mental decline as measured by the Modified Mini-Mental State Exam - a test that evaluates memory, language, abstract reasoning and other cognitive functions.
Also, these benefits were clearly due to direct intake of centrally active ACE inhibitors and not just by exposure to this particular class of hypertension drugs.
According to Kaycee Sink, M.D., M.A.S., lead researcher and an assistant professor of internal medicine - gerontology:
"For older adults who are going to take an ACE inhibitor drug for blood pressure control, it makes sense for their doctors to prescribe one that goes into the brain.
These results suggest that there is more to treating blood pressure than achieving a goal of 140/80. Which drug you choose for blood pressure control can have broader implications.
We know that ACE inhibitors protect against heart failure and kidney failure, and now there is evidence that some of them may also protect against dementia."
While these results are truly promising, still confirmation is needed in a more randomly selected patient population.
Find more details from the full report.
Permalink: Centrally Active ACE Inhibitors May Help Reduce Risk of Cognitive Decline in Older Adults
Tags:
ACE
inhibitors
risk
of
dementia
decline
of
cognitive
function
and
memory
hypertension
drugs
help
con
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/68224
Mr Wong
Vote for Centrally Active ACE Inhibitors May Help Reduce Risk of Cognitive Decline in Older Adults:
|
Rating: 6.50 out of 2 vote(s) cast.
|
Response from:
Sandeep singh
(05/02/09 2:21am)
Altace is indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease or diabetes that is accompanied by at least one other cardiovascular risk factor ( hypertension, high levels of total cholesterol, low HDL levels, cigarette smoking or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke or death from cardiovascular causes.
Response from:
PharmaGazette
Check out the following great posts from the blogosphere that I think would interest pharma business readers as well: Centrally Active ACE inhibitors May Help Reduce Risk of Cognitive Decline in Older Adults Twinject, Now With Enhanced Features Diabete...
Subscribe
Use the search to look for other interesting posts
| RSS | See all blog subscribe options |
|
What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |









